Sensitivity to BET inhibition is correlated to amplification and/or overexpression of the respective driver genes in both medulloblastoma and neuroblastoma, i.e., MYC and MYCN, respectively [24,26,47]. The gene discussed is DNER; the disease is neuroblastoma.